LEO Science & Tech Hub (The Hub), a research and development unit of LEO Pharma, has initiated 2 collaborative projects with The Wellman Center for Photomedicine at Massachusetts General Hospital.
The Hub, which identifies, develops, and funds innovative solutions that improve the lives of patients with skin diseases, will provide research funding to support development of novel imaging technology using a disposable microbiopsy device. Conor L Evans, PhD, assistant professor, Harvard Medical School, will lead the project. The Evans Lab’s specializes in microscopy and spectroscopy for understanding cancer and dermatology disorders. The research project collaboration will explore novel imagine technologies that will to enable non-invasive, high-resolution, real-time pharmacokinetic/pharmacodynamic measurements with help of the lab’s coherent Raman scattering (CRS) technology (Figure 1).
Figure 1. Coherent Raman imaging may one day allow real-time biological measurements to benefit patients. Here’s an image of mouse skin “tuned” into the vibrational frequencies of lipids taken at the surface of skin and shows hairs and the hexagonally packed corneocytes.
The second project includes work with Walfre Franco, PhD, clinical instructor, and Adam Raff, MD, PhD, clinical associate from R Rox Anderson’s Lab. The Anderson Lab will focus on discovering new optical treatments and diagnostics for dermatologic applications, and will seek to develop a suture-free and disposable microbiopsy device that may allow for a non-scarring sampling procedure of full-thickness skin microbiopsies.
"We are excited to enter these collaborations with the Wellman Center for Photomedicine at Mass General Hospital and are honored to work with scientists at the forefront of imaging technology and microbiopsy research,” said Michael Sierra, PhD, VP, The Hub. “At LEO Science & Tech Hub, we firmly believe in the power of collective effort and are always seeking cutting-edge technologies to advance non-invasive biopsy and imaging technologies for patients with skin diseases.”
—Julie Gould (Mazurkiewicz)
LEO Science & Tech Hub (The Hub), a research and development unit of LEO Pharma, has initiated 2 collaborative projects with The Wellman Center for Photomedicine at Massachusetts General Hospital.
The Hub, which identifies, develops, and funds innovative solutions that improve the lives of patients with skin diseases, will provide research funding to support development of novel imaging technology using a disposable microbiopsy device. Conor L Evans, PhD, assistant professor, Harvard Medical School, will lead the project. The Evans Lab’s specializes in microscopy and spectroscopy for understanding cancer and dermatology disorders. The research project collaboration will explore novel imagine technologies that will to enable non-invasive, high-resolution, real-time pharmacokinetic/pharmacodynamic measurements with help of the lab’s coherent Raman scattering (CRS) technology (Figure 1).
Figure 1. Coherent Raman imaging may one day allow real-time biological measurements to benefit patients. Here’s an image of mouse skin “tuned” into the vibrational frequencies of lipids taken at the surface of skin and shows hairs and the hexagonally packed corneocytes.
The second project includes work with Walfre Franco, PhD, clinical instructor, and Adam Raff, MD, PhD, clinical associate from R Rox Anderson’s Lab. The Anderson Lab will focus on discovering new optical treatments and diagnostics for dermatologic applications, and will seek to develop a suture-free and disposable microbiopsy device that may allow for a non-scarring sampling procedure of full-thickness skin microbiopsies.
"We are excited to enter these collaborations with the Wellman Center for Photomedicine at Mass General Hospital and are honored to work with scientists at the forefront of imaging technology and microbiopsy research,” said Michael Sierra, PhD, VP, The Hub. “At LEO Science & Tech Hub, we firmly believe in the power of collective effort and are always seeking cutting-edge technologies to advance non-invasive biopsy and imaging technologies for patients with skin diseases.”
—Julie Gould (Mazurkiewicz)
LEO Science & Tech Hub (The Hub), a research and development unit of LEO Pharma, has initiated 2 collaborative projects with The Wellman Center for Photomedicine at Massachusetts General Hospital.
The Hub, which identifies, develops, and funds innovative solutions that improve the lives of patients with skin diseases, will provide research funding to support development of novel imaging technology using a disposable microbiopsy device. Conor L Evans, PhD, assistant professor, Harvard Medical School, will lead the project. The Evans Lab’s specializes in microscopy and spectroscopy for understanding cancer and dermatology disorders. The research project collaboration will explore novel imagine technologies that will to enable non-invasive, high-resolution, real-time pharmacokinetic/pharmacodynamic measurements with help of the lab’s coherent Raman scattering (CRS) technology (Figure 1).
Figure 1. Coherent Raman imaging may one day allow real-time biological measurements to benefit patients. Here’s an image of mouse skin “tuned” into the vibrational frequencies of lipids taken at the surface of skin and shows hairs and the hexagonally packed corneocytes.
The second project includes work with Walfre Franco, PhD, clinical instructor, and Adam Raff, MD, PhD, clinical associate from R Rox Anderson’s Lab. The Anderson Lab will focus on discovering new optical treatments and diagnostics for dermatologic applications, and will seek to develop a suture-free and disposable microbiopsy device that may allow for a non-scarring sampling procedure of full-thickness skin microbiopsies.
"We are excited to enter these collaborations with the Wellman Center for Photomedicine at Mass General Hospital and are honored to work with scientists at the forefront of imaging technology and microbiopsy research,” said Michael Sierra, PhD, VP, The Hub. “At LEO Science & Tech Hub, we firmly believe in the power of collective effort and are always seeking cutting-edge technologies to advance non-invasive biopsy and imaging technologies for patients with skin diseases.”
In this interview, Dr Doris Day discussed her session, "Global Approach for Facial Rejuvenation," presented at the 26th Annual Mount Sinai Winter Symposium.
In this interview, Dr Doris Day discussed her session, "Global Approach for Facial Rejuvenation," presented at the 26th Annual Mount Sinai Winter Symposium.
Researchers conducted a retrospective analysis aimed to investigate the prevalence and clinical implications of atopic dermatitis in patients with psoriatic arthritis undergoing biologic therapy.
Researchers conducted a retrospective analysis aimed to investigate the prevalence and clinical implications of atopic dermatitis in patients with psoriatic arthritis undergoing biologic therapy.
In this interview, Dr Ramone F. Williams discusses the Mohs Surgeons Leading the Future program and highlights the program's objectives, the specific projects undertaken, and the valuable lessons learned by participants in enhancing their...
In this interview, Dr Ramone F. Williams discusses the Mohs Surgeons Leading the Future program and highlights the program's objectives, the specific projects undertaken, and the valuable lessons learned by participants in enhancing their...
How do you guide patients through peer-driven misinformation and anxiety-provoking online forums? Take this quiz to refine your approach to trusted resources and patient-centered reassurance.
How do you guide patients through peer-driven misinformation and anxiety-provoking online forums? Take this quiz to refine your approach to trusted resources and patient-centered reassurance.
Master the first-visit conversation for AA patients. Quiz yourself on how to balance hope with realism, address comorbid atopy, and respond to the quest for deeper causality in autoimmune disease.
Master the first-visit conversation for AA patients. Quiz yourself on how to balance hope with realism, address comorbid atopy, and respond to the quest for deeper causality in autoimmune disease.
